About Us

Global

R&D

Investor Relations

About Us

Leading the pharmaceutical industry to become a superior provider of pharmaceutical products and services.

1993 Year
Founded in 1993
1800 +
There are more than 1800 pharmaceutical R&D personnel
70 +
Export to 70 countries and regions
500 +
The group is developing 500 products
820 +
820 patents granted
1993 Year
Founded in 1993
1800 +
There are more than 1800 pharmaceutical R&D personnel
70 +
Export to 70 countries and regions
500 +
The group is developing 500 products
820 +
820 patents granted
Global

Adhere to R&D innovation and international expansion.

EPIC Pharma

St. Louis Research and Development Center

PuraCap Pharmaceutical

Humanwell Pharma Mali

Humanwell Pharma Afrique

Humanwell Pharmaceutical Ethiopia

YiChang Humanwell Pharmaceutical

Humanwell Puracap Phamaceuticals (Wuhan)

Likang Pharmaceutical

Paion Pharma

Paion UK

Xinjiang Xipa Pharmaceutical

EPIC Pharma

Having the qualifications for the production and operation of controlled drugs and holding over 60 ANDA approvals; Having a mature sales network in the US market; A CMO site recognized by multinational pharmaceutical companies for a long time.

St. Louis Research and Development Center

The company's important strategic layout for promoting internationalization includes cutting-edge information research, new drug discovery and exploration, high-end formulation research and industrialization, and coordinated development with the international registration, production, export, and independent marketing of the company's products. Focusing on strategic areas such as anesthesia, analgesia, and central nervous system diseases, there are products under research in innovative drugs, high-end sustained-release formulations, and complex injection formulations.

PuraCap Pharmaceutical

PuraCap Pharmaceuticals LLC, established in 2008 in New Jersey, is among the earliest Chineses-backed pharmaceutical companies in the USA. The company is engaged in the market entry and distribution of OTC products in the US, and its specialty products are soft gel capsules.

Humanwell Pharma Mali

Commercial pharmaceutical company covering eight French speaking regions in West Africa

Humanwell Pharma Afrique

The first modern pharmaceutical factory in West Africa, ending the history of Mali being unable to produce drugs; Production of injectable, oral solid/liquid and other preparations

Humanwell Pharmaceutical Ethiopia

Modern pharmaceutical factories in Ethiopia; the first pharmaceutical factory invested in and constructed by a Hubei enterprise in Ethiopia; production of oral solid/liquid formulations and small volume injections.

YiChang Humanwell Pharmaceutical

The first oral solid dosage form factory in Hubei Province to be certified by the US FDA and the UK MHRA; Focus on the research and development, registration, production, and international sales of sustained-release oral solid preparations and transdermal generic drugs that meet national standards.

Humanwell Puracap Phamaceuticals (Wuhan)

The first soft capsule production enterprise in Hubei Province to pass the US FDA certification; Leading supplier of soft capsule drug formulations in the US market; A leading enterprise in the research and production of global soft capsule drug formulations.

Likang Pharmaceutical

Having dual qualifications from NMPA and FDA, covering injections and high-end oral solid preparations, we undertake the entire process of clinical sample to commercial production commissioning business.

Paion Pharma

Headquartered in Aachen of Germany, the company focuses on the R&D and commercialization of innovative pharmaceutical products for anesthesia and critical care.

Xinjiang Xipa Pharmaceutical

The company established a subsidiary in the Republic of Uzbekistan in 2016, and established a professional marketing academic promotion team and registration team. The company has registered six kinds of Uyghur medicines, and the sales scope covers the entire territory of Uzbekistan.

Continue to build and improve the high-end technology platform, and promote the technology transfer and introduction of new products through industry-university-research cooperation.

More than 500 products under development, and over 30 new Class 1 drugs under development

826 authorized patents, 389 invention patents, and 82 overseas authorized patents

Covering Europe, the United States, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, Taiwan, China and other countries and regions


Continuously building and improving high-end technology platforms, promoting technology transfer and introduction of new products through industry university research cooperation

While building a first-class R&D innovation platform, we provide comprehensive services for new drug research, development, clinical trials, and registration


We have a research team centered around overseas pharmaceutical experts, domestic pharmaceutical PhDs, and master’s degree holders

There are over 1800 R&D personnel, including more than 200 PhDs, and 7 experts who enjoy special allowances from the State Council

Investor Relations
Periodical Ad-hoc
0.303624s